Cardiorenal Syndrome in End-Stage Kidney Disease

Kazuhiko Tsuruya, Masahiro Eriguchi, Shunsuke Yamada, Hideki Hirakata, Takanari Kitazono

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Cardiorenal syndrome (CRS) in patients with end-stage kidney disease (ESKD) represents mainly cardiovascular disease (CVD) due to various complications associated with renal dysfunction-defined as type 4 CRS by Ronco et al.-because the effect of cardiac dysfunction on the kidneys does not need to be taken into consideration, unlike in non-dialysis dependent chronic kidney disease (CKD). Summary: Patients with ESKD are often in a state of chronic inflammation due to the upregulation of proinflammatory cytokines. Chronic inflammation leads to malnutrition and consequently to vascular endothelial dysfunction and vascular calcification, which is referred to as malnutrition-inflammation-atherosclerosis (MIA) syndrome and acts as a major risk factor for CVD. Anemia also plays a crucial role in CVD, and individuals with erythropoietin-resistant anemia have a particularly high risk of CVD. However, caution is emphasized because not only anemia itself, but also the overtreatment of anemia with erythropoiesis-stimulating agents aimed at elevating hemoglobin to ≥13 g/dl can also increase the risk of CVD. In CKD-mineral and bone disorder (CKD-MBD), phosphate load triggers the interactions between various factors such as calcium, parathyroid hormone, vitamin D, and fibroblast growth factor 23, promoting vascular calcification and thus becoming a risk factor for CVD. Key Messages: In addition to traditional atherosclerosis risk factors such as hypertension, diabetes, and dyslipidemia, the involvement of MIA syndrome, anemia, and CKD-MBD accompanying CKD have also become a focus for investigation as major players in CRS in patients with ESKD.

Original languageEnglish
Pages (from-to)337-343
Number of pages7
JournalBlood Purification
Volume40
Issue number4
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

Cardio-Renal Syndrome
Chronic Kidney Failure
Cardiovascular Diseases
Anemia
Chronic Renal Insufficiency
Malnutrition
Inflammation
Vascular Calcification
Atherosclerosis
Hematinics
Chronic Kidney Disease-Mineral and Bone Disorder
Kidney
Dyslipidemias
Erythropoietin
Parathyroid Hormone
Vitamin D
Blood Vessels
Hemoglobins
Up-Regulation
Phosphates

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Cardiorenal Syndrome in End-Stage Kidney Disease. / Tsuruya, Kazuhiko; Eriguchi, Masahiro; Yamada, Shunsuke; Hirakata, Hideki; Kitazono, Takanari.

In: Blood Purification, Vol. 40, No. 4, 01.12.2015, p. 337-343.

Research output: Contribution to journalArticle

Tsuruya, Kazuhiko ; Eriguchi, Masahiro ; Yamada, Shunsuke ; Hirakata, Hideki ; Kitazono, Takanari. / Cardiorenal Syndrome in End-Stage Kidney Disease. In: Blood Purification. 2015 ; Vol. 40, No. 4. pp. 337-343.
@article{768e54bd7c214b10941dfde805201fc9,
title = "Cardiorenal Syndrome in End-Stage Kidney Disease",
abstract = "Background: Cardiorenal syndrome (CRS) in patients with end-stage kidney disease (ESKD) represents mainly cardiovascular disease (CVD) due to various complications associated with renal dysfunction-defined as type 4 CRS by Ronco et al.-because the effect of cardiac dysfunction on the kidneys does not need to be taken into consideration, unlike in non-dialysis dependent chronic kidney disease (CKD). Summary: Patients with ESKD are often in a state of chronic inflammation due to the upregulation of proinflammatory cytokines. Chronic inflammation leads to malnutrition and consequently to vascular endothelial dysfunction and vascular calcification, which is referred to as malnutrition-inflammation-atherosclerosis (MIA) syndrome and acts as a major risk factor for CVD. Anemia also plays a crucial role in CVD, and individuals with erythropoietin-resistant anemia have a particularly high risk of CVD. However, caution is emphasized because not only anemia itself, but also the overtreatment of anemia with erythropoiesis-stimulating agents aimed at elevating hemoglobin to ≥13 g/dl can also increase the risk of CVD. In CKD-mineral and bone disorder (CKD-MBD), phosphate load triggers the interactions between various factors such as calcium, parathyroid hormone, vitamin D, and fibroblast growth factor 23, promoting vascular calcification and thus becoming a risk factor for CVD. Key Messages: In addition to traditional atherosclerosis risk factors such as hypertension, diabetes, and dyslipidemia, the involvement of MIA syndrome, anemia, and CKD-MBD accompanying CKD have also become a focus for investigation as major players in CRS in patients with ESKD.",
author = "Kazuhiko Tsuruya and Masahiro Eriguchi and Shunsuke Yamada and Hideki Hirakata and Takanari Kitazono",
year = "2015",
month = "12",
day = "1",
doi = "10.1159/000441583",
language = "English",
volume = "40",
pages = "337--343",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Cardiorenal Syndrome in End-Stage Kidney Disease

AU - Tsuruya, Kazuhiko

AU - Eriguchi, Masahiro

AU - Yamada, Shunsuke

AU - Hirakata, Hideki

AU - Kitazono, Takanari

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Cardiorenal syndrome (CRS) in patients with end-stage kidney disease (ESKD) represents mainly cardiovascular disease (CVD) due to various complications associated with renal dysfunction-defined as type 4 CRS by Ronco et al.-because the effect of cardiac dysfunction on the kidneys does not need to be taken into consideration, unlike in non-dialysis dependent chronic kidney disease (CKD). Summary: Patients with ESKD are often in a state of chronic inflammation due to the upregulation of proinflammatory cytokines. Chronic inflammation leads to malnutrition and consequently to vascular endothelial dysfunction and vascular calcification, which is referred to as malnutrition-inflammation-atherosclerosis (MIA) syndrome and acts as a major risk factor for CVD. Anemia also plays a crucial role in CVD, and individuals with erythropoietin-resistant anemia have a particularly high risk of CVD. However, caution is emphasized because not only anemia itself, but also the overtreatment of anemia with erythropoiesis-stimulating agents aimed at elevating hemoglobin to ≥13 g/dl can also increase the risk of CVD. In CKD-mineral and bone disorder (CKD-MBD), phosphate load triggers the interactions between various factors such as calcium, parathyroid hormone, vitamin D, and fibroblast growth factor 23, promoting vascular calcification and thus becoming a risk factor for CVD. Key Messages: In addition to traditional atherosclerosis risk factors such as hypertension, diabetes, and dyslipidemia, the involvement of MIA syndrome, anemia, and CKD-MBD accompanying CKD have also become a focus for investigation as major players in CRS in patients with ESKD.

AB - Background: Cardiorenal syndrome (CRS) in patients with end-stage kidney disease (ESKD) represents mainly cardiovascular disease (CVD) due to various complications associated with renal dysfunction-defined as type 4 CRS by Ronco et al.-because the effect of cardiac dysfunction on the kidneys does not need to be taken into consideration, unlike in non-dialysis dependent chronic kidney disease (CKD). Summary: Patients with ESKD are often in a state of chronic inflammation due to the upregulation of proinflammatory cytokines. Chronic inflammation leads to malnutrition and consequently to vascular endothelial dysfunction and vascular calcification, which is referred to as malnutrition-inflammation-atherosclerosis (MIA) syndrome and acts as a major risk factor for CVD. Anemia also plays a crucial role in CVD, and individuals with erythropoietin-resistant anemia have a particularly high risk of CVD. However, caution is emphasized because not only anemia itself, but also the overtreatment of anemia with erythropoiesis-stimulating agents aimed at elevating hemoglobin to ≥13 g/dl can also increase the risk of CVD. In CKD-mineral and bone disorder (CKD-MBD), phosphate load triggers the interactions between various factors such as calcium, parathyroid hormone, vitamin D, and fibroblast growth factor 23, promoting vascular calcification and thus becoming a risk factor for CVD. Key Messages: In addition to traditional atherosclerosis risk factors such as hypertension, diabetes, and dyslipidemia, the involvement of MIA syndrome, anemia, and CKD-MBD accompanying CKD have also become a focus for investigation as major players in CRS in patients with ESKD.

UR - http://www.scopus.com/inward/record.url?scp=84949783458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949783458&partnerID=8YFLogxK

U2 - 10.1159/000441583

DO - 10.1159/000441583

M3 - Article

C2 - 26657922

AN - SCOPUS:84949783458

VL - 40

SP - 337

EP - 343

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 4

ER -